Epstein-Barr nuclear antigen 1-derived peptide–Major Histocompatibility Complex (EBNA1-pMHC)

Epstein-Barr nuclear antigen 1 (EBNA1)-derived peptide–Major Histocompatibility Complex (MHC) complexes are specialized molecular structures presented on the surface of cells infected with Epstein-Barr virus (EBV) or EBV-associated tumor cells (Source: PubMed 35121880). EBNA1 is a viral protein required for the persistence and replication of the EBV genome, and it is uniquely expressed in all forms of EBV latency, making it a near-universal marker for EBV-associated diseases (Source: UniProt P03211). While the EBNA1 protein resides within the nucleus, it is naturally processed by the cellular proteasome into short peptides that are then loaded onto MHC Class I or Class II molecules for presentation to the immune system (Source: PubMed 15163936). These peptide-MHC (pMHC) complexes serve as the primary target for CD8+ and CD4+ T cells, which recognize them via specific T-cell receptors (TCRs). In therapeutic contexts, these complexes are targeted by adoptive T-cell therapies, such as Tabelecleucel, and experimental TCR-engineered T cells or TCR-like antibodies designed to treat EBV-driven malignancies like nasopharyngeal carcinoma and post-transplant lymphoproliferative disorder (Source: PubMed 36543865, PubMed 22496601). Targeting these complexes allows for the selective elimination of virally transformed cells while sparing healthy EBV-negative tissue, although challenges such as HLA downregulation and potential cross-reactivity with self-antigens remain (Source: PubMed 35025758).

Other names

EBNA1-HLA complexEBNA1 peptide-MHC complexEBNA1-MHC class I complexEBNA1-MHC class II complexEBNA1-HLA-A*02:01 complex

Recognition of the specific EBNA1 peptide-MHC complex by T-cell receptors (TCRs) or TCR-like molecules, triggering cytotoxic T-lymphocyte (CTL) activity and selective destruction of EBV-positive cells (Source: PubMed 35121880).